BrightInsight and Sanofi's Collaboration Yields Positive Results for Patient App
BrightInsight, Inc. (SNY), a leader in digital health solutions, has announced promising new data from its collaboration with Sanofi and partner Regeneron. The focus of this partnership is the recently developed Patient App, which has demonstrated a significant positive impact on treatment adherence and persistence for one of Sanofi and Regeneron’s key biologic therapies. This collaboration highlights the ongoing challenge of patient adherence, especially with self-injected therapies.
Adherence Challenges in Pharmaceuticals
Adherence to prescribed medication remains a critical issue in the pharmaceutical industry, particularly with home-administered therapies. According to studies from the World Health Organization, adherence rates can plummet to as low as 50%, with a marked decline often seen after the first year. Moreover, research indicates that between 35% and 63% of patients discontinue therapy within the first year for chronic and specialty treatments.
Impact of the Patient App
The Patient App, tailored specifically to support patients undergoing treatment with Sanofi and Regeneron’s biologic therapy, has proven effective in addressing these adherence challenges. Since its limited launch, the app has been embraced by over 25,000 patients, showcasing its user-friendly design and practical relevance.
An analysis of data from over 6,000 patients reveals that those utilizing the Patient App exhibit higher engagement levels and increased consistency in their treatment regimens. Notably, real-world observational data highlights a 4% lower discontinuation rate and improved adherence after one year among Patient App users compared to non-users.
Quotes from Leadership
Kal Patel, CEO and Co-Founder of BrightInsight, expressed pride in the partnership, stating, “We’re honored that Sanofi and its partner, Regeneron, have trusted BrightInsight with the patient experience of a critical medicine. While patient apps have historically had limited impact, we’ve helped Sanofi and Regeneron build a transformative digital solution that truly understands the patient’s disease journey.”
Emmanuel Frenehard, Chief Digital Officer at Sanofi, added, “At Sanofi, we’re committed to transforming the patient experience through scalable, high-impact digital solutions. With BrightInsight, we’ve developed a solution for patients that also delivers measurable impact in therapy adherence and persistence.”
Future Expansion Plans
The partnership between Sanofi and BrightInsight is set to expand into key international markets, further leveraging the global capabilities of the BrightInsight Platform across Sanofi’s specialty care portfolio. This strategic move underscores the importance of digital solutions in enhancing patient care.
About BrightInsight
BrightInsight is recognized as a leading partner for biopharma in delivering compliant digital health solutions across the patient and provider journey. We provide state-of-the-art technology to help life sciences companies rapidly develop and scale digital solutions that meet market needs. By collaborating with BrightInsight, companies ensure the compliance of their digital health products, even as they adapt across different geographical regions.
Contact Information
For more information, please visit BrightInsight’s website and official social media channels. For media inquiries, contact:
- Helen Shik
- Shik Communications
- Phone: 1.617.510.4373
- Email: helen@shikcommunications.com